Bayer: Dieser Ex-FDP politician is a new pharmaceutical chief lobbyist

photo alliance / Schoening | Shoes

The company is active in the United States and Milliarden-Klagen: Bayer’s pharmaceutical and chemical industries are not making any progress with Krisen mode. Obwohl der Gesamtmarkt wuchs, halbierte sich der Wert des Konzerns in letzten otherthalb Jahren. There are other people at the top of CEO Bill Anderson, who works under Druck.

In the meantime: The Pharmabereich (“Bayer Pharmaceuticals”) is in line with the other Sparten “Consumer Health” (“Personal Health) and “Crop Science” (Landwirtschaft) right there. I have a quarter of the capacity at 4.6 billion euros stacked, the profit margin of quickly 30 Prozent is the highest price.

Pharma area with high margins

Trotzdem kämpft auch Pharmaceuticals with high energy costs, strong legislation from the Australian country and stricter regulations at EU and national level. Since the arrival of Brussels in the future, the information provided by Business Insider will be well-founded and well-founded.

They will decide on the Konzern den Posten des internationalen Cheflobbyisten (Global Head of Public Affairs) in November with a long-term FDP Bundestagsabgeordneten, the Health Politician Lars Lindemann.